
-
Lexicon Pharmaceuticals Inc NasdaqGS:LXRX Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its orally-delivered small molecule drug candidates under development include sotagliflozin for the treatment of hypertrophic cardiomyopathy or HCM and type 1 diabetes that is in Phase 3 clinical trial; LX9211, which has completed Phase II clinical trials for the treatment of neuropathic pain; and LX9851 for the treatment of obesity and associated cardiometabolic disorders, as well as for weight management. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Location: 2445 Technology Forest Boulevard, The Woodlands, TX, 77381, United States | Website: https://www.lexpharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
162M
Cash
194.8M
Avg Qtr Burn
-41.86M
Short % of Float
20.29%
Insider Ownership
1.15%
Institutional Own.
74.93%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
XERMELO® (telotristat ethyl) Details Carcinoid syndrome diarrhea | Approved Quarterly sales | |
INPEFA™ (SOTAGLIFLOZIN) Details Heart disease, Heart failure | Approved Quarterly sales | |
ZYNQUISTA™ (sotagliflozin) Details Hypertrophic cardiomyopathies | Phase 3 Data readout | |
Pilavapadin (LX9211) Details Neuropathy, Diabetic peripheral neuropathy | Phase 2b Update | |
LX9851 Details Obesity, Cardiovascular disease | IND Submission | |
ZYNQUISTA™ (sotagliflozin) Details Type 1 diabetes, Diabetes | Failed Discontinued |